Results 201 to 210 of about 93,268 (298)

Targeting WDR12 Unleashes T‐Cell‐Mediated Antitumor Activity in Melanoma by Destabilizing CD276

open access: yesAdvanced Science, EarlyView.
WDR12 cooperates with the chaperonin subunit CCT7 to maintain CD276 stability on tumor cells, suppressing T‐cell activity and promoting immune escape. SU14813, a small‐molecule WDR12 inhibitor, reduces CD276 stability and relieves CD276‐mediated T‐cell suppression.
Jie Pan   +10 more
wiley   +1 more source

Transcriptome profiling of tumor-infiltrating lymphocyte-mediated cytotoxicity against patient-derived lung cancer organoids. [PDF]

open access: yesCommun Biol
Qin Z   +14 more
europepmc   +1 more source

Eye‐Brain Neuroimmune Axis Enables Long‐Term Survival in Glioblastoma by Modulating Brain Immune Surveillance and Neuronal Excitability

open access: yesAdvanced Science, EarlyView.
The eye–brain neuroimmune axis triggers immune activation and disrupts pathological neuronal connectivity to extend glioblastoma survival. ABSTRACT As an anatomical extension of the central nervous system (CNS), the eye harbors rich neural and immune interfaces with the brain. However, the integrated immunological and neurological nexus between the eye
Mingyue Cui   +9 more
wiley   +1 more source

Nano‐Confined Radical Anion as An NIR‐II Photothermal Immunogenic Amplifier for In Situ Cancer Vaccination

open access: yesAdvanced Science, EarlyView.
A nano‐confined radical anion acts as a photothermal immunogenic amplifier. Kinetically stabilized nanoparticles couple high near‐infrared‐II (NIR‐II) photothermal efficacy with glutathione (GSH) depletion to boost reactive oxygen species (ROS) and immunogenic cell death (ICD).
Mengxin Mu   +9 more
wiley   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

open access: yesAdvanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy